Genotype-Phenotype Correlations for Putative Haploinsufficient Genes in Deletions of 6q26-q27: Report of Eight Patients and Review of Literature

Abstract

Background Cytogenomic analyses have been used to detect pathogenic copy number variants. Patients with deletions at 6q26-q27 present variable clinical features. We reported clinical and cytogenomic findings of eight unrelated patients with a deletion of 6q26-q27. A systematic review of the literature found 28 patients with a deletion of 6q26-q27 from 2010 to 2020.
Results For these 36 patients, the sex ratio showed equal occurrence between males and females; 29 patients (81%) had a terminal deletion and seven patients (19%) had a proximal or distal interstitial deletion. Of the 22 patients with parental studies, deletions of de novo, maternal, paternal, and bi-parental inheritance accounted for 64, 18, 14, and 4% of patients, respectively. The most common clinical findings were brain abnormalities (100%) in fetuses observed by ultrasonography followed by developmental delay and intellectual disability (81%), brain abnormalities (72%), facial dysmorphism (66%), hypotonia (63%), learning difficulty or language delay (50%), and seizures (47%) in pediatric and adult patients. Anti-epilepsy treatment showed the effect on controlling seizures in these patients. Cytogenomic mapping defined one proximal critical region at 6q26 containing the putative haploinsufficient gene PRKN and one distal critical region at 6q27 containing two haploinsufficient genes DLL1 and TBP. Deletions involving the PRKN gene could associate with early-onset Parkinson disease and autism spectrum disorder; deletions involving the DLL1 gene correlate with the 6q terminal deletion syndrome.
Conclusion The genotype-phenotype correlations for putative haploinsufficient genes in deletions of 6q26-q27 provided evidence for precise diagnostic interpretation, genetic counseling, and clinical management of patients with a deletion of 6q26-q27.

Keywords

deletions of 6q26-q27 / array comparative hybridization / haploinsufficient gene / genotype-phenotype correlations

References

[1] Ravnan JB, Tepperberg JH, Papenhausen P.et al.Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet 2006; 43(06): 478-489

[2] Stevenson DA, Brothman AR, Carey JC.et al.6q subtelomeric deletion: is there a recognizable syndrome?. Clin Dysmorphol 2004; 13(02): 103-106

[3] Bertini V, De Vito G, Costa R, Simi P, Valetto A.Isolated 6q terminal deletions: an emerging new syndrome. Am J Med Genet A 2006; 140(01): 74-81

[4] Eash D, Waggoner D, Chung J, Stevenson D, Martin CL.Calibration of 6q subtelomere deletions to define genotype/phenotype correlations. Clin Genet 2005; 67(05): 396-403

[5] Striano P, Malacarne M, Cavani S.et al.Clinical phenotype and molecular characterization of 6q terminal deletion syndrome: five new cases. Am J Med Genet A 2006; 140(18): 1944-1949

[6] Elia M, Striano P, Fichera M.et al.6q terminal deletion syndrome associated with a distinctive EEG and clinical pattern: a report of five cases. Epilepsia 2006; 47(05): 830-838

[7] Rooms L, Reyniers E, Scheers S.et al.TBP as a candidate gene for mental retardation in patients with subtelomeric 6q deletions. Eur J Hum Genet 2006; 14(10): 1090-1096

[8] Lee JY, Cho YH, Hallford G.Delineation of subtelomeric deletion of the long arm of chromosome 6. Ann Hum Genet 2011; 75(06): 755-764

[9] Xiang B, Li A, Valentin D, Nowak NJ, Zhao H, Li P.Analytical and clinical validity of whole-genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay. Am J Med Genet A 2008; 146A(15): 1942-1954

[10] Xiang B, Zhu H, Shen Y.et al.Genome-wide oligonucleotide array comparative genomic hybridization for etiological diagnosis of mental retardation: a multicenter experience of 1499 clinical cases. J Mol Diagn 2010; 12(02): 204-212

[11] Chai H, DiAdamo A, Grommisch B. et al. A retrospective analysis of 10-year data assessed the diagnostic accuracy and efficacy of cytogenomic abnormalities in current prenatal and pediatric settings. Front Genet 2019; 10: 1162

[12] Mosca AL, Callier P, Masurel-Paulet A.et al.Cytogenetic and array-CGH characterization of a 6q27 deletion in a patient with developmental delay and features of Ehlers-Danlos syndrome. Am J Med Genet A 2010; 152A(05): 1314-1317

[13] Valduga M, Philippe C, Bach Segura P.et al.A retrospective study by oligonucleotide array-CGH analysis in 50 fetuses with multiple malformations. Prenat Diagn 2010; 30(04): 333-341

[14] Rigon C, Salviati L, Mandarano R, Donà M, Clementi M.6q27 subtelomeric deletions: is there a specific phenotype?. Am J Med Genet A 2011; 155A(05): 1213-1214

[15] Dupé V, Rochard L, Mercier S.et al.NOTCH, a new signaling pathway implicated in holoprosencephaly. Hum Mol Genet 2011; 20(06): 1122-1131

[16] Gerber JC, Neuhann TM, Tyshchenko N, Smitka M, Hackmann K.Expanding the clinical and neuroradiological phenotype of 6q27 microdeletion: olfactory bulb aplasia and anosmia. Am J Med Genet A 2011; 155A(08): 1981-1986

[17] Li P, Pomianowski P, DiMaio MS. et al. Genomic characterization of prenatally detected chromosomal structural abnormalities using oligonucleotide array comparative genomic hybridization. Am J Med Genet A 2011; 155A(07): 1605-1615

[18] Wadt K, Jensen LN, Bjerglund L, Lundstrøm M, Kirchhoff M, Kjaergaard S.Fetal ventriculomegaly due to familial submicroscopic terminal 6q deletions. Prenat Diagn 2012; 32(12): 1212-1217

[19] Conti V, Carabalona A, Pallesi-Pocachard E.et al.Periventricular heterotopia in 6q terminal deletion syndrome: role of the C6orf70 gene. Brain 2013; 136(Pt 11): 3378-3394

[20] Peddibhotla S, Nagamani SC, Erez A.et al.Delineation of candidate genes responsible for structural brain abnormalities in patients with terminal deletions of chromosome 6q27. Eur J Hum Genet 2015; 23(01): 54-60

[21] De Cinque M, Palumbo O, Mazzucco E.et al.Developmental coordination disorder in a patient with mental disability and a mild phenotype carrying terminal 6q26-qter deletion. Front Genet 2017; 8: 206

[22] Thakur M, Bronshtein E, Hankerd M.et al.Genomic detection of a familial 382 Kb 6q27 deletion in a fetus with isolated severe ventriculomegaly and her affected mother. Am J Med Genet A 2018; 176(09): 1985-1990

[23] Williams ES, Barrett MJ, Dhamija R.et al.Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN. Mol Genet Genomic Med 2018; 6(03): 457-462

[24] Hanna MD, Moretti PNP.P de Oliveira C, et al. Defining the critical region for intellectual disability and brain malformations in 6q27 microdeletions. Mol Syndromol 2019; 10(04): 202-208

[25] Puvabanditsin S, Negroponte E, Jang P, Hedges A, Kased R, Mehta R.Multiple congenital anomalies in a patient with interstitial 6q26 deletion. Mol Syndromol 2020; 10(05): 276-280

[26] Zou Z, Huang L, Lin S.et al.Prenatal diagnosis of posterior fossa anomalies: additional value of chromosomal microarray analysis in fetuses with cerebellar hypoplasia. Prenat Diagn 2018; 38(02): 91-98

[27] Iwamoto H, Muroi A, Sekine T, Tsurubuchi T, Ishikawa E, Matsumura A.Unusual form of obstructive hydrocephalus in association with 6q terminal deletion syndrome: a case report and literature review. Pediatr Neurosurg 2019; 54(06): 419-423

[28] Riggs ER, Andersen EF, Cherry AM.et al.Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med 2020; 22(02): 245-257

[29] Denison SR, Callahan G, Becker NA, Phillips LA, Smith DI.Characterization of FRA6E and its potential role in autosomal recessive juvenile parkinsonism and ovarian cancer. Genes Chromosomes Cancer 2003; 38(01): 40-52

[30] Xu F, Li L, Schulz VP.et al.Cytogenomic mapping and bioinformatic mining reveal interacting brain expressed genes for intellectual disability. Mol Cytogenet 2014; 7(01): 4

[31] Fischer-Zirnsak B, Segebrecht L, Schubach M.et al.Haploinsufficiency of the Notch ligand DLL1 causes variable neurodevelopmental disorders. Am J Hum Genet 2019; 105(03): 631-639

[32] de Angelis MH, McIntyre II J, Gossler A. Maintenance of somite borders in mice requires the delta homologue DII1. Nature 1997; 386(6626): 717-721

[33] Koide R, Kobayashi S, Shimohata T.et al.A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease?. Hum Mol Genet 1999; 8(11): 2047-2053

[34] Balikova I, Menten B, de Ravel T. et al. Subtelomeric imbalances in phenotypically normal individuals. Hum Mutat 2007; 28(10): 958-967

[35] Zhang HZ, Li P, Wang D.et al.FOXC1 gene deletion is associated with eye anomalies in ring chromosome 6. Am J Med Genet A 2004; 124A(03): 280-287

[36] Yin CL, Chen HI, Li LH.et al.Genome-wide analysis of copy number variations identifies PARK2 as a candidate gene for autism spectrum disorder. Mol Autism 2016; 7: 23

[37] Zhang X, Abdellaoui A, Rucker J.et al.Genome-wide burden of rare short deletions is enriched in major depressive disorder in four cohorts. Biol Psychiatry 2019; 85(12): 1065-1073

[38] Backx L, Fryns JP, Marcelis C, Devriendt K, Vermeesch J, Esch HV.Haploinsufficiency of the gene Quaking (QKI) is associated with the 6q terminal deletion syndrome. Am J Med Genet A 2010; 152A(02): 319-326

[39] Lauriat TL, Shiue L, Haroutunian V.et al.Developmental expression profile of quaking, a candidate gene for schizophrenia, and its target genes in human prefrontal cortex and hippocampus shows regional specificity. J Neurosci Res 2008; 86(04): 785-796

RIGHTS & PERMISSIONS

2022 Global Medical Genetics